Earnings Call · Q1 FY2026·2026-04-27

Q1 26EPS +16.67%·Rev n/aQ4 25EPS -1.47%·Rev n/aQ3 25EPS -6.90%·Rev n/aQ2 25EPS +3.45%·Rev n/a⚠ consensus missing

Fulcrum Therapeutics, Inc. FULC

Alexander Sapir — See Remarks

Alan Musso — Chief Financial Officer

−1.5%1d on move date−1.7% vs SPY3d−8.8%5d−6.1%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more FULC calls or request research access.

More FULC calls Browse calls Request research access